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Abstract
Background: Malaria caused by Plasmodium vivax is a major public health problem worldwide that affects 70-80
million people in the Middle East, Asia, Western Pacific, South America and the Caribbean. Despite its
epidemiological importance, few antigens from this parasite species have been characterized to date compared to
Plasmodium falciparum, due in part to the difficulties of maintaining an in vitro culture of P. vivax. This study
describes the identification of the P. falciparum thrombospondin-related apical merozoite protein homologue in
P. vivax (PvTRAMP) and examines its potential to be further evaluated as vaccine candidate.
Methods: The gene encoding PvTRAMP was identified through an extensive search of the databases hosting the
genome sequence of P. vivax. Genes adjacent to pvtramp were identified in silico to determine the degree of
similarity between the protein sequences encoded by equivalent chromosomic fragments in P. falciparum and
Plasmodium knowlesi.T h epvtramp gene was amplified from cDNA of P. vivax schizont stages, cloned and
expressed in Escherichia coli. Anti-PvTRAMP antisera was obtained by inoculating rabbits with PvTRAMP B cell
epitopes produced as synthetic peptides in order to assess its recognition in parasite lysates by Western blot and
in intact parasites by indirect immunofluorescence. The recognition of recombinant PvTRAMP by sera from P. vivax-
infected individuals living in endemic areas was also assessed by ELISA.
Results: The PfTRAMP homologue in P. vivax, here denoted as PvTRAMP, is a 340-amino-acid long antigen
encoded by a single exon that could have a potential role in cytoadherence, as indicated by the presence of a
thrombospondin structural homology repeat (TSR) domain. According to its transcription and expression profile,
PvTRAMP is initially located at the parasite’s apical end and later on the parasite surface. Recombinant PvTRAMP is
recognized by sera from infected patients, therefore, indicating that it is targeted by the immune system during a
natural infection with P. vivax.
Conclusions: The results of this work support conducting further studies with PvTRAMP to evaluate its
immunogenicity and protection-inducing ability in the Aotus animal model.
Background
Five Plasmodium species are known to cause malaria in
humans: Plasmodium falciparum, Plasmodium vivax,
Plasmodium malariae, Plasmodium ovale and Plasmo-
dium knowlesi. Of these five species, P. falciparum and
P. vivax have the largest epidemiological impact, with
P. falciparum malaria accounting for over 1 million deaths
and around 300 million new cases annually [1], while
P. vivax malaria has long been neglected and mistakenly
considered a “benign” disease, but it is now gaining impor-
tance as it causes a considerable number of cases (~70-80
million cases per year), especially in the Middle East, Asia,
the Western Pacific, South America and the Caribbean.
Plasmodium vivax statistics could be even larger because
it easily be misdiagnosed in endemic areas, where co-
infection is frequent [2,3].
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compared to P. falciparum due to its tropism for reticu-
locytes, which account for less than 1% of the total
circulating red blood cell (RBC) count and, therefore,
makes it difficult to maintain an in vitro culture of
this species [4]. However, the release of the complete
genome sequences of P. falciparum and P. vivax [5,6],
their corresponding transcriptome profiles [7,8], and the
analysis of the P. falciparum proteome [9,10] have pro-
moted studies aimed at identifying proteins involved in
parasite invasion to host cells, such as proteins of the
secretory apical organelles and surface proteins of blood-
stage parasites. Based on this large body of available data,
recent research in P. vivax malaria has made use of bioin-
formatics tools to identify and characterize new potential
anti-malarial vaccine candidates by homology compari-
son (e.g. P. vivax vs. P. falciparum) [11-14].
The apical organelle complex of merozoites (the para-
site’s blood stage responsible for RBC invasion) plays an
important role in parasite entry into RBCs. Tubular
secretory structures, known as micronemes, belong to
this complex; these secrete large amounts of proteins
that are used by the parasite to adhere and invade host
cells selectively [15-18]. It has recently been found that
several of these invasion-related proteins contain
domains that are highly conserved among the different
apicomplexan species, such as the thrombospondin
structural homology repeat (TSR) domain. TSR domains
usually bind to highly variable sulfated glycoconjugates
on the host cell surface that mediate cell-cell and/or cell-
matrix interactions, therefore, conferring better host-cell
binding specificity [19-22]. In essence, TSR domains are
crucial for many biological processes and their functional
relevance has been suggested based on the identification
of this domain in relatively distant organisms [22].
To date, several apicomplexan antigens have been asso-
ciated to the TSR family [20]. In Plasmodium,t h em o s t
well characterized family members are found in sporo-
zoites and include: the thrombospondin-related adhesive
protein (TRAP), which is a conserved microneme protein
important for parasite motility and for the infection of
mosquito salivary glands and human hepatocytes [23];
the circumsporozoite protein (CSP), which is the most
important sporozoite surface protein and is involved in
gliding motility, among other functions; the CS related-
TRAP protein (CTRP), which is an ookinete protein
important for invasion of mosquito midguts [20,24];
PfSPATR, which contains an altered thrombospondin
Type I repeat domain important for hepatocyte invasion
and is expressed both on sporozoite surface and the
micronemes of merozoites [25]; and finally, PTRAMP
(initially identified in P. falciparum and here denoted as
PfTRAMP), which has been shown to be expressed dur-
ing the asexual intraerythrocytic cycle, with a maximum
transcription peak during late schizonts. Besides contain-
ing a conventional TSR domain, PfTRAMP has an apical
localization pattern in early schizonts and is later relo-
cated to the surface of merozoites prior to schizont
rupture.
Based on the importance of Plasmodium thrombos-
pondin-like proteins and considering the results regard-
ing the expression, transcription profile and cellular
localization of PfTRAMP, as well as the in vitro affinity
of chemically-synthesized peptides of PfTRAMP to RBCs
[26,27], the aim of this study was to identify and charac-
terize the PfTRAMP homologue in P. vivax:P v T R A M P ,
and conduct studies to determine its antigenicity.
Methods
Source of P. vivax parasites
The Vivax Colombia Guaviare 1 (VCG-1) strain was used
as a source of P. vivax DNA, RNA, and proteins. In brief,
parasites were cultured in vivo by successive passes
in splenectomized Aotus monkeys [28] captured in the
Amazon jungle with permission of the Colombian govern-
ment (CORPOAMAZONIA) and kept at FIDIC’s primate
station in Leticia (Amazonas, Colombia). Monkeys were
taken care of according to the guidelines stipulated by the
Colombian Ministry of Health (law 84/1989) and the
Office for Protection from Research Risks (OPRR, Depart-
ment of Health and Human Service, USA), under the con-
stant supervision of a primatologist. Levels of parasitaemia
were assessed daily by Acridine Orange staining and mon-
keys were immediately treated whenever levels were ≥5%,
or before if the monkey’s health condition had deterio-
rated. Treatment consisted of orally administered paedia-
tric doses of anti-malarial drugs as follows: 10 mg/kg of
chloroquine on the first day and 7.5 mg/kg per day until
day five, administered with 0.25 mg/kg of primaquine
starting on day 3 and continuing until day 5. Once total
clearance of parasites from blood had been confirmed and
monkeys were in a satisfactory health conditions, they
were released back into their natural habitat close to the
site where they had been captured, with the supervision of
CORPOAMAZONIA officials.
Isolation of parasite genomic DNA and in silico gene
analysis
Late-stage infected RBCs (mainly schizonts) were iso-
lated from 3-4 mL samples of monkey blood using a
discontinuous Percoll gradient, as previously reported
elsewhere [29]. Genomic DNA was extracted from
P. vivax infected-RBCs using the Wizard DNA purifica-
tion system kit (Promega, Wisconsin, USA) and used as
template for PCR amplification. Primers were designed
based on the sequence of a putative transcript encoding
the PfTRAMP homologue in P. vivax, which was identi-
fied by screening the genome sequence of the P. vivax
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amino acid sequence of the PfTRAMP as BLAST query.
The databases hosting the complete genome sequences
of P. falciparum and P. knowlesi were also screened
with GenScan and GeneComber [31,32] in order to
identify open reading frames (ORFs) adjacent to pftramp
and pktramp. Identity and similarity values of peptide
sequences between P. vivax-P. falciparum and P. vivax-
P. knowlesi were obtained using the ALignX tool from
the VectorNTI Suite 9 bioinformatics software package
(Invitrogen, California, USA).
RNA extraction, cDNA synthesis, cloning and sequencing
Total parasite RNA (1 μg) was extracted by the Trizol
method [33] and subsequently treated with RQ1 RNase
free DNase (Promega, Wisconsin, USA). A 20 μLa l i q u o t
of RNA was used a template for RT-PCR cDNA synthesis
using the SuperScript III enzyme (Invitrogen, California,
USA), according to manufacturer’s recommendations.
Briefly, cDNA was synthesized for 60 min at 50°C and
then amplified by PCR with Platinum Pfx DNA polymer-
ase (Invitrogen, California, USA) using pvtramp specific
forward (5′-atgTACATTTTGCAGTTGCTCC-3′)a n d
reverse (5′-TTCATACATAAATCTGCCAGC-3′)p r i -
mers, for 35 cycles at the following temperatures: 94°C
for 15 s, 54°C for 30 s, 68°C for 60 s and a final 5 min
extension at 68°C. Primers were designed to exclude the
first 29 amino acids of PvTRAMP. An additional PCR
was carried out using non-reverse transcribed RNA as
template to be used as negative control and rule out
genomic DNA contamination. RT-PCR products were
cloned into the pEXP5-CT/TOPO vector (Invitrogen,
California, USA). Recombinant plasmid DNA was puri-
fied using the UltraClean mini plasmid prep purification
kit (MO BIO laboratories, California, USA) and the integ-
rity of the cloned insert was confirmed by sequencing of
two clones obtained from independent PCR assays using
an automatic ABI PRISM 310 Genetic Analyzer (PE
Applied Biosystems, California, USA). The obtained
nucleotide sequences, as well as their corresponding
amino acid sequences, were aligned to the hypothetical
pvtramp sequence reported for the Sal-1 reference strain.
Expression and purification of rPvTRAMP
Recombinant PvTRAMP (rPvTRAMP) was obtained by
cloning the pvtramp gene into the pEXP5-CT/TOPO
vector. A six-histidine tag was added to the protein’s
C-terminus to allow purification and immunodetection
by anti-histidine monoclonal antibodies. Briefly, Escheri-
chia coli BL21-AI (Invitrogen) transformed with the
pvtramp-pEXP5 vector were grown in 1 L of Terrific
Broth containing 0.1 mg/mL ampicillin. Expression of
PvTRAMP was induced by adding 0.2% arabinose (w/v)
and incubating cells for 5 h at 37°C. Bacteria were
pelleted by centrifugation at 12,000 × g for 30 min at 4°C
and then resuspended in extraction buffer containing
6-8 M urea, 15 mM imidazole, 10 mM Tris-Cl, 100 mM
NaH2PO4, 10 mg/mL lysozyme and protease inhibitors
and lysed by sonication. To isolate rPvTRAMP, the lysate
was centrifuged at 12,000 × g for 30 min at 4°C and the
supernatant was mixed with Ni
+2-NTA resin (Qiagen,
California, USA), previously balanced to pH 8.0 with
extraction buffer. Non-retained proteins were eluted with
t h es a m eb u f f e r ,w h i l et h er P v T R A M P 6his was eluted
from the resin using extraction buffer with increasing
concentrations of imidazole (50 mM, 100 mM, 200 mM
and 500 mM). All fractions were analysed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting (see below). Pure protein
fractions were pooled and dialyzed against 1 × PBS,
pH 5.5, as a protein refolding step. The total amount of
protein was determined by the bicinchoninic acid assay
(BCA).
Peptide synthesis
B cell linear epitopes were searched for in the putative
sequence of P. vivax Sal-1 PvTRAMP using BepiPred at
a default threshold of 0.35 and 75% of specificity [34].
Taking into account Parker’s antigenicity, solvent acces-
sibility and hydrophobicity values from ANTHEPROT
[35], three 20-mer-long peptides were selected for pep-
tide synthesis. The sequences of these peptides in single
letter code were:
51AVGAGSQLGQAAQESDVNRK
70,
82NSQFTNEKVLEVYSSKEENV
101 and
155DVKNPSE-
FEILSEPIKFSIS
174. Peptides were synthesized by stan-
dard solid-phase t-Boc/Bzl peptide synthesis [36], adding
glycine and cysteine residues at the N- and C-terminal
ends, respectively, to allow polymerization. The peptides
were lyophilized and then characterized by RP-HPLC
and MALDI-TOF MS.
Polyclonal antibodies against rPvTRAMP
Three New Zealand rabbits were subcutaneously inocu-
lated at multiple sites with the three PvTRAMP B cell
linear epitopes mentioned above. Peptides were adminis-
tered as a 150 μg mixture of polymerized synthetic pep-
tides, emulsified in Freund’s complete adjuvant (FCA)
f o rt h ef i r s td o s e( d a y0 )a n di nF r e u n d ’si n c o m p l e t e
adjuvant (FIA) for the second and third doses (days 21
and 42). Sera were collected before the first inoculation
to obtain pre-immune sera and 21 days after the third
immunization to obtain hyper-immune sera.
SDS-PAGE and Western blotting
Malarial parasites isolated from total blood samples of
P. vivax-infected Aotus monkeys were lysed with 20%
SDS, 0.5 M EDTA, 100 mM PMSF, and 100 mM iodoa-
cetamide. Proteins in the parasite lysate were separated
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lose membrane. Purified recombinant protein was
loaded into the same gel as positive control. The mem-
brane was blocked with 5% skimmed milk in PBS-0.05%
Tween, washed thrice with PBS-0.05% Tween for 5 min
and then cut into strips to assess recognition by each
rabbit’s serum. Strips were incubated with a 1:40 dilu-
tion of rabbit sera for 1 h at room temperature, then
washed thrice with PBS-0.05% Tween and incubated at
room temperature for 1 h with 1:4,500 alkaline phos-
phatase-coupled goat anti-rabbit IgG. Excess of antibody
was removed by washing strips thrice with PBS-0.05%
Tween and color development was assessed using the
BCIP/NBT kit (Promega, Madison, USA), according to
manufacturer’s instructions. The positive control strip
was incubated for 1 h with 1:4,500 peroxidase coupled
anti-polyhistidine monoclonal antibody diluted in 5%
skimmed milk-PBS-0.05% Tween, washed thrice with
PBS-0.05% Tween and then treated with VIP peroxidase
substrate (Vector Laboratories, Burlingame, Canada).
Recognition of rPvTRAMP by sera from P. vivax-infected
individuals
The recognition of rPvTRAMP by sera from P. vivax
infected individuals was assessed by ELISA. In brief, sera
were collected from 20 individuals who inhabited a
P. vivax malaria endemic area in Colombia and had an
active episode of P. vivax malaria at the time of blood
withdrawal, as well as from three healthy individuals
who lived in a non-endemic area and had never had an
episode of P. vivax malaria (negative controls). All indi-
viduals were explained about the objective of the study
and signed an informed consent form before blood
withdrawal. All procedures were evaluated and approved
by FIDIC’se t h i c sc o m m i t t e e .P o l y s o r bp l a t e sw e r e
coated with purified rPvTRAMP (1 μg/well), incubated
f i r s ta t3 7 ° Cf o r1h ,t h e na t4 ° Co v e r n i g h ta n do n c e
more at 37°C for 1 h. Each well was washed thrice with
PBS-0.05% Tween and then blocked with 200 μLo f5 %
skimmed milk in PBS-0.05% Tween for 1 h. Sera were
added to the plates in duplicate as a 1:100 dilution in
5% skimmed milk PBS-0.05% Tween and incubated at
37°C for 1 h. Plates were then washed thrice with PBS-
0.05% Tween and incubated for 1 h at 37°C with 100 μL
of a 1:4,000 dilution of peroxidase conjugated anti-
human IgG as secondary antibody. Excess of peroxidase-
coupled antibody was removed by washing plates thrice
with PBS-0.05% Tween. Colour development was evalu-
ated using the TMB Microwell Peroxidase Substrate
solution kit KPL Laboratories, Washington, USA) and
optical density (OD) measures at 620 nm using a micro-
plate reader (Labsystems Multiskan MJ ELISA reader).
Indirect immunofluorescence assays
Thin blood smears of P. vivax-infected monkeys (3-5%
parasitaemia) were prepared on glass slides, then fixed
with acetone/methanol, chilled at 4°C and blocked PBS-
10% Fetal Calf Serum (FCS) for 1 h at 37°C. Slides were
then incubated inside a humid chamber for 1 h at 37°C
with primary antibody (rabbit anti-synthetic peptides’
polyclonal antibodies) diluted to 1:20 in blocking buffer,
then washed thrice with PBS and incubated with a 1:40
dilution of goat anti-rabbit IgG-fluorescein isothiocya-
nate conjugate (Sigma, Missouri, USA). Finally, slides
were stained with 2 μg/mL of DAPI for 20 min at room
temperature and examined using an Olympus BX51
fluorescence microscope.
Results and Discussion
Identification and characterization of the gene encoding
TRAMP in P. vivax
A PfTRAMP homologue was identified in P. vivax by
screening the entire P. vivax genome sequence retrieved
from the JCVI database using the PfTRAMP sequence
[GenBank: AAN36262.1, PlasmoDB: PFL0870w] as
query for tBLASTn analyses. The pvtramp gene is
located in a 3,120,417 bp chromosomic segment [Plas-
moDB: CM000455], which contains a 1,023-bp ORF
[PlasmoDB: PVX_123575], encoding a 340 amino-acid-
long protein with a theoretical mass of 39 kDa.
Additionally, a search for genes orthologous to pftramp
on the PlasmoDB protein database identified similar genes
in Plasmodium chabaudi (Pch), Plasmodium berghei (Pb),
Plasmodium yoelii (Py)a n dPlasmodium knowlesi (Pk).
Based on a previous phylogenetic analyses showing shorter
divergence time between P. vivax and P. knowlesi [37], this
latter species was chosen, together with P. falciparum,t o
compare the chromosomic region containing the putative
pvtramp gene. The alignment showed homology between
the ORFs encoding PvTRAMP and PfTRAMP, as well as
high overall identity (Id) and similarity (S) values between
the protein sequences derived from pvtramp, pftramp and
pktramp (Id = 54.55% and S = 83.25%). To confirm gene/
chromosome synteny between the 3 species, the chromo-
somic regions containing the three tramp genes were
compared (23.5 kbp in P. vivax, 21.5 kbp in P. falciparum
and 24 kbp in P. knowlesi), observing that the upstream
and downstream orientation of ORFs as well as the exon-
intron composition are conserved among the three spe-
cies. This is consistent with identity and similarity values
obtained when comparing the three tramp g e n e sa sw e l l
as the peptide sequences derived from genes adjacent to
pvtramp, pftramp and pktramp, which showed Id and S
values of 33.3-70.2% and 46.3-81%, respectively between
P. vivax-P. falciparum, and Id and S values of 69.2-95.2%
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(Figure 1).
PvTRAMP is 12 residues shorter than its homologue
PfTRAMP (41 kDa) and contains a hydrophobic region
at its N-terminus, which is consistent with a signal pep-
tide according to SignalP v3.0 [38]. In PvTRAMP the
signal peptide cleavage site lies between amino acids 20
and 21 (AIS-EK) (Figure 2a), while in PfTRAMP it lies
between amino acids 24 and 25 (ISS-ND). PvTRAMP
seems to have a C-terminal transmembrane domain
(TM) according to the TMHMM v.2.0 [39] prediction
server hosted at the Center for Biological Sequence
Analysis of the Technical University of Denmark [40],
which had been also predicted for PfTRAMP [26].
A single TSR domain was detected in PvTRAMP
when the sequence was analyzed using the InterProScan
[InterPro: IPR000884] and PFAM [PFAM: PF00090]
databases. This TSR domain has a high significance
value and spans from residue 234 to 284, thus lying
close to the TM domain (Figure 2a). In general, it has
approximately 50-60 amino acids in length, and contains
12 or more highly conserved and typically separated
residues comprising 6 cysteines (C), 2 to 3 tryptophans
(W) and 2 arginines (R) [19]. The crystal structure
showed that this domain is divided into two sub-groups
(1 and 2) depending on the rearrangements between
conserved cysteines and the disposition of aromatic resi-
dues, which determine the folding of the major helix in
the protein’s structure [26]. The TSR domain is highly
conserved among the different apicomplexan species
and is characterized by the presence of one or multiple
copies of type I human thrombospondin domain. In
general, it has a distinctive amino acid sequence
(EWSPCSVTCGXGXRXR), preceded by the sequence
WX (where X is generally an acid residue), which is an
interesting aspect since the presence of two conserved
tryptophan residues is not very frequent in Plasmodium
spp. [20,26]. It is important to mention that the main
function of this domain lies in its amino-terminal motif
which mediates binding to glycosaminoglycans (GAG); a
characteristic that is associated with the invasion ability
of parasite proteins containing TSR domains [23,41].
The disposition of the TSR domain of PvTRAMP is
consistent with studies on PfTRAMP by Thompson
et al [26], where it has been shown that the classical
architecture of the domain is not altered by some resi-
due substitutions. Same as other TSR domains,
PvTRAMP has a characteristic arrangement of six
cysteine residues defining three highly conserved motifs
that are particularly significant for structure and binding
functions and is conserved among P. vivax, P. falci-
parum and P. knowlesi. The first is an amino-terminal
W**WG*W motif (where * represents any residue),
although the first tryptophan is substituted by a tyrosine
in PvTRAMP and PfTRAMP. The second motif, CS/
T*TC, shows an unusual threonine ® aspartic acid sub-
stitution, whose functional significance is still unclear.
Finally, the third motif (I/R/Q*R*R) is thought to be
intercalated between the conserved tryptophan residues
and is also present in PvTRAMP [26].
pvtramp is transcribed in parasite asexual stages
The RNA isolated from the parasite blood stages was
treated with DNAse to avoid contamination with geno-
mic DNA and used as template for reverse transcription.
The sizes of the PCR and RT-PCR amplification pro-
ducts agreed with the size expected based on sequence
for pvtramp without including the first 29 amino acids
(963 bp) (Figure 2b). This result shows that PvTRAMP
is encoded by a single 1,023-pb exon, which was con-
firmed by sequencing of genomic DNA and cDNA pro-
ducts from independents PCR assays.
No substitutions were found when comparing the
sequences from the VCG-1 strain (Aotus-adapted strain)
Figure 1 Schematic representation of pftramp, pvtramp and pktramp. The figure shows the localization of the genes encoding PfTRAMP,
PkTRAMP (both in gray) and PvTRAMP (in black) in P. falciparum, P. knowlesi and P. vivax chromosomic fragments, respectively, as well as the
localization of the adjacent genes evaluated in this study. The arrows above each box indicate the ORF orientation, while the boxes show
distribution and organization of the exons along the chromosomal segments. Genes are assigned according to their annotation in PlasmoDB.
These chromosomic fragments comprised 21.5 kbp from the P. falciparum chromosome 12 (695,001-716,500 pb), 23.5 kbp from the P. vivax
contig CM000455 (1,519,501-1,543,000 pb) and 24 kbp from the P. knowlesi chromosome 14 (1,548,001-1,572,000 pb).
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pared to the sequence reported for the Sal-1 strain, sug-
gesting, therefore, that pvtramp is highly conserved
among isolates obtained from different geographic
regions. However, this needs to be confirmed by com-
paring a larger number of strains [28].
PvTRAMP is expressed in P. vivax asexual stages
Based on the PvTRAMP sequence reported for the Sal-1
strain, three 20 mer-long synthetic peptides were
designed, taking care of selecting peptides outside the
TSR domain (amino acids 232 to 285) in order to avoid
cross-reactivity with other proteins containing TSR
domains (Figure 2a). Immunochemistry assays with
polyclonal sera obtained by immunizing three New Zeal-
and rabbits with a mixture of these three peptides
showed that PvTRAMP is expressed in late intraerythro-
cytic parasite stages (schizonts), as has been previously
described for its PfTRAMP homologue [26]. Hyperim-
mune but not pre-immune polyclonal rabbit sera raised
against the peptide mixture recognized a 37-kDa band
by Western blot when purified recombinant PvTRAMP
was size separated by 12% SDS-PAGE, which is consis-
tent with the weight expected for PvTRAMP based on
its sequence (Figure 2c). Likewise, the Western blot ana-
lysis of polyclonal rabbit sera against a schizont-rich
P. vivax protein lysate showed recognition of a 37-kDa
band by the hyperimmune sera but not by the pre-
immune sera (Figure 2d).
Immunofluorescence assays using blood smears from
P. vivax-infected Aotus monkeys and pooled rabbit
hyperimmune sera as primary antibody detected
PvTRAMP in schizont stages. As shown in Figure 3, a
fluorescence pattern typical of merozoite surface proteins
with some apparent concentration towards the apical
pole was observed, which is similar to the fluorescence
pattern reported for PfTRAMP. Localization assays per-
formed by Thompson et al [26] using a combination of
antisera against the rhoptry-associated protein RAP1 and
the apical membrane antigen AMA1 showed that
PfTRAMP co-localizes with AMA-1 in apical organelles
from early schizonts, but displays a distinct localization
pattern compared to RAP1 [26,42]. This has lead the
authors to suggest that PfTRAMP originates at the
micronemes and relocalizes to merozoite surface before
initiation of RBC invasion. Further confocal microscopy
studies with more specific antibodies would help defining
whether P. vivax TRAMP exhibits this localization
pattern.
rPvTRAMP recognition by human sera
An ELISA test was performed to evaluate the degree of
recognition of rPvTRAMP by sera from 20 patients who
had an active P. vivax infection at the moment of blood
Figure 2 (A) Schematic representation of PvTRAMP indicating the localizations of the predicted signal peptide and transmembrane
domain (both in dark gray), as well as the TSR domain (light gray). Localization of the conserved cysteines inside the TSR domain and the
synthetic peptides used in this study to obtain anti-PvTRAMP antisera are indicated by arrow heads and white boxes, respectively. (B) PCR
amplification of pvtramp from P. vivax genomic DNA and cDNA. Lane 1. Amplification from genomic DNA using primers designed based on the
sequence predicted for pvtramp. Lane 2. RT-PCR product amplified from DNAse-treated total P. vivax RNA. (C) Recognition of purified rPvTRAMP
by anti-PvTRAMP rabbit sera, as assessed by Western blot. Lane 1: pre-immune sera. Lane 2: hyperimmune sera. Lane H: recognition of purified
rPvTRAMP by anti-polyhistidine monoclonal antibody. (D) Western blot analysis of a P. vivax lysate with anti-PvTRAMP rabbit sera. Lane 1: pre-
immune sera. Lane 2: hyperimmune sera.
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P. vivax malaria during their lifetime. Most sera showed
a high recognition of rPvTRAMP with OD values that
were significantly higher than the highest OD value
obtained for the negative controls plus twice the stan-
dard deviation (Figure 4). However, for most sera,
recognition of the refolded protein was not notably
greater compared to recognition of the protein obtained
under denaturing conditions. This may suggest that (1)
PvTRAMP exhibits both linear and conformational epi-
topes during a natural infection, both of which have the
potential to stimulate the host’s immune response, or
( 2 )t h a tt h er e f o l d i n gs t e pw a sn o ts u f f i c i e n tf o r
rPvTRAMP to fold back properly and therefore it did
not acquire a 3D structure similar to that of the native
protein expressed by the parasite (probably because of
its high cysteine content), as the immune system’s
recognition of conformational epitopes is usually predo-
minant for Plasmodium proteins involved in invasion
[12,43,44]. Because of this, it would be important to
obtain PvTRAMP in native conditions and performing
functional assays to evaluate its activity.
Conclusions
The transcription and expression profile of PvTRAMP,
its merozoite surface localization and its high degree of
conservation when compared with homologous proteins
from other Plasmodium species have been determined
Figure 3 Cellular localization of PvTRAMP as assessed by IFA using hyper-immune anti-PvTRAMP rabbit sera as primary antibody. (A-
C) Detection of P. vivax in early schizont stages. (D-I) Parasites in late schizont stage (segmented). The figure shows fluorescence with DAPI and
FITC staining, and the merging of both.
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Page 8 of 10in the present study. Moreover, the high yield obtained
when expressing PvTRAMP as a recombinant protein
and the broad recognition by sera from P. vivax-infected
people support further studies aimed at evaluating its
immunogenicity and protective ability (as a full protein
or its derived synthetic peptides) in a relevant biological
model, such as the Aotus monkey.
Acknowledgements
We would like to thank Laura Natalia Soler, Milena Jineth Sanchez and
Oswaldo Escobar for their technical support, to Gisselle Rivera for translating
the manuscript and to Professor Manuel Elkin Patarroyo for his invaluable
comments and suggestions. In memory of Professor Gerardo Pérez.
Author details
1Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50 No. 26-
20, Bogotá, Colombia.
2Universidad del Rosario, Calle 63D No. 24-31, Bogotá,
Colombia.
Authors’ contributions
AM designed experiments, analysed data and wrote the final manuscript.
DIA carried out assays, interpreted the results and wrote the initial draft.
DAMP performed IFA experiments, obtained all the polyclonal sera and
tabulated the results. SVG carried out DNA extraction, PCR amplification and
cloning assays. HA was in charge of expressing and purifying the
recombinant protein. MV provided purified synthetic peptides for rabbit
immunizations. MAP evaluated and coordinated assays, critically revised the
manuscript and gave the final approval for its publication. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 April 2010 Accepted: 13 October 2010
Published: 13 October 2010
References
1. WHO: World malaria report. The WHO global malaria programme 2008.
2. Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden of
Plasmodium vivax malaria. Am J Trop Med Hyg 2001, 64:97-106.
3. Galinski MR, Barnwell JW: Plasmodium vivax: who cares? Malar J 2008,
7(Suppl 1):S9.
4. Golenda CF, Li J, Rosenberg R: Continuous in vitro propagation of the
malaria parasite Plasmodium vivax. Proc Natl Acad Sci USA 1997,
94:6786-6791.
5. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM,
Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K,
Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B,
Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW,
Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA,
McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC,
Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B:
Genome sequence of the human malaria parasite Plasmodium
falciparum. Nature 2002, 419:498-511.
Figure 4 ELISA showing reactivity of sera from P. vivax-infected patients against rPvTRAMP. Columns 1-20 correspond to recognition by
sera from P. vivax malaria patients. Columns 21-23 showed recognition of rPvTRAMP by healthy individuals that had never had an episode of P.
vivax malaria. rPvTRAMP used in this assay was resuspended in urea and thoroughly dialyzed against PBS for its refolding. Each column is shown
with its corresponding standard deviation.
Mongui et al. Malaria Journal 2010, 9:283
http://www.malariajournal.com/content/9/1/283
Page 9 of 106. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J,
Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del
Portillo HA, Essien K, Feldblyum TV, Fernandez-Becerra C, Gilson PR,
Gueye AH, Guo X, Kang’a S, Kooij TW, Korsinczky M, Meyer EV, Nene V,
Paulsen I, White O, Ralph SA, Ren Q, Sargeant TJ, Salzberg SL, Stoeckert CJ,
Sullivan SA, Yamamoto MM, Hoffman SL, Wortman JR, Gardner MJ,
Galinski MR, Barnwell JW, Fraser-Liggett CM: Comparative genomics of the
neglected human malaria parasite Plasmodium vivax. Nature 2008,
455:757-763.
7. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL: The
transcriptome of the intraerythrocytic developmental cycle of
Plasmodium falciparum. PLoS Biol 2003, 1:E5.
8. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, Russell B, Ginsburg H,
Nosten F, Day NP, White NJ, Carlton JM, Preiser PR: The transcriptome of
Plasmodium vivax reveals divergence and diversity of transcriptional
regulation in malaria parasites. Proc Natl Acad Sci USA 2008,
105:16290-16295.
9. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD,
Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y,
Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ: A proteomic view
of the Plasmodium falciparum life cycle. Nature 2002, 419:520-526.
10. Hall N, Karras M, Raine JD, Carlton JM, Kooij TW, Berriman M, Florens L,
Janssen CS, Pain A, Christophides GK, James K, Rutherford K, Harris B,
Harris D, Churcher C, Quail MA, Ormond D, Doggett J, Trueman HE,
Mendoza J, Bidwell SL, Rajandream MA, Carucci DJ, Yates JR, Kafatos FC,
Janse CJ, Barrell B, Turner CM, Waters AP, Sinden RE: A comprehensive
survey of the Plasmodium life cycle by genomic, transcriptomic, and
proteomic analyses. Science 2005, 307:82-86.
11. Angel DI, Mongui A, Ardila J, Vanegas M, Patarroyo MA: The Plasmodium
vivax Pv41 surface protein: identification and characterization. Biochem
Biophys Res Commun 2008, 377:1113-1117.
12. Mongui A, Angel DI, Guzman C, Vanegas M, Patarroyo MA: Characterisation
of the Plasmodium vivax Pv38 antigen. Biochem Biophys Res Commun
2008, 376:326-330.
13. Mongui A, Perez-Leal O, Rojas-Caraballo J, Angel DI, Cortes J, Patarroyo MA:
Identifying and characterising the Plasmodium falciparum RhopH3
Plasmodium vivax homologue. Biochem Biophys Res Commun 2007,
358:861-866.
14. Patarroyo MA, Perez-Leal O, Lopez Y, Cortes J, Rojas-Caraballo J, Gomez A,
Moncada C, Rosas J, Patarroyo ME: Identification and characterisation of
the Plasmodium vivax rhoptry-associated protein 2. Biochem Biophys Res
Commun 2005, 337:853-859.
15. Preiser P, Kaviratne M, Khan S, Bannister L, Jarra W: The apical organelles
of malaria merozoites: host cell selection, invasion, host immunity and
immune evasion. Microbes Infect 2000, 2:1461-1477.
16. Scholtyseck E, Mehlhorn H: Ultrastructural study of characteristic
organelles (paired organelles, micronemes, micropores) of sporozoa and
related organisms. Z Parasitenkd 1970, 34:97-127.
17. Treeck M, Struck NS, Haase S, Langer C, Herrmann S, Healer J, Cowman AF,
Gilberger TW: A conserved region in the EBL proteins is implicated in
microneme targeting of the malaria parasite Plasmodium falciparum. J
Biol Chem 2006, 281:31995-32003.
18. Wertheimer SP, Barnwell JW: Plasmodium vivax interaction with the
human Duffy blood group glycoprotein: identification of a parasite
receptor-like protein. Exp Parasitol 1989, 69:340-350.
19. Dubremetz JF, Garcia-Reguet N, Conseil V, Fourmaux MN: Apical organelles
and host-cell invasion by Apicomplexa. Int J Parasitol 1998, 28:1007-1013.
20. Naitza S, Spano F, Robson KJ, Crisanti A: The thrombospondin-related
protein family of Apicomplexan parasites: the gears of the cell invasion
machinery. Parasitol Today 1998, 14:479-484.
21. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J,
Wang JH: Crystal structure of the TSP-1 type 1 repeats: a novel layered
fold and its biological implication. J Cell Biol 2002, 159:373-382.
22. Tucker RP: The thrombospondin type 1 repeat superfamily. Int J Biochem
Cell Biol 2004, 36:969-974.
23. Wengelnik K, Spaccapelo R, Naitza S, Robson KJ, Janse CJ, Bistoni F,
Waters AP, Crisanti A: The A-domain and the thrombospondin-related
motif of Plasmodium falciparum TRAP are implicated in the invasion
process of mosquito salivary glands. Embo J 1999, 18:5195-5204.
24. Nussenzweig V, Nussenzweig RS: Circumsporozoite proteins of malaria
parasites. Cell 1985, 42:401-403.
25. Chattopadhyay R, Rathore D, Fujioka H, Kumar S, de la Vega P, Haynes D,
Moch K, Fryauff D, Wang R, Carucci DJ, Hoffman SL: PfSPATR, a
Plasmodium falciparum protein containing an altered thrombospondin
type I repeat domain is expressed at several stages of the parasite life
cycle and is the target of inhibitory antibodies. J Biol Chem 2003,
278:25977-25981.
26. Thompson J, Cooke RE, Moore S, Anderson LF, Janse CJ, Waters AP:
PTRAMP; a conserved Plasmodium thrombospondin-related apical
merozoite protein. Mol Biochem Parasitol 2004, 134:225-232.
27. Calderon JC, Curtidor H, Gonzalez O, Cifuentes G, Reyes C, Patarroyo ME:
High affinity interactions between red blood cell receptors and synthetic
Plasmodium thrombospondin-related apical merozoite protein (PTRAMP)
peptides. Biochimie 2008, 90:802-810.
28. Pico de Coana Y, Rodriguez J, Guerrero E, Barrero C, Rodriguez R,
Mendoza M, Patarroyo MA: A highly infective Plasmodium vivax strain
adapted to Aotus monkeys: quantitative haematological and molecular
determinations useful for P. vivax malaria vaccine development. Vaccine
2003, 21:3930-3937.
29. Andrysiak PM, Collins WE, Campbell GH: Concentration of Plasmodium
ovale-a n dPlasmodium vivax-infected erythrocytes from nonhuman
primate blood using Percoll gradients. Am J Trop Med Hyg 1986,
35:251-254.
30. J. Craig Venter Institute. [http://www.jcvi.org/].
31. Burge C, Karlin S: Prediction of complete gene structures in human
genomic DNA. J Mol Biol 1997, 268:78-94.
32. Shah SP, McVicker GP, Mackworth AK, Rogic S, Ouellette BF: GeneComber:
combining outputs of gene prediction programs for improved results.
Bioinformatics 2003, 19:1296-1297.
33. Chomczynski P: A reagent for the single-step simultaneous isolation of
RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993,
15:532-534, 536-537.
34. Larsen JE, Lund O, Nielsen M: Improved method for predicting linear B-
cell epitopes. Immunome Res 2006, 2:2.
35. Geourjon C, Deleage G, Roux B: ANTHEPROT: an interactive graphics
software for analyzing protein structures from sequences. J Mol Graph
1991, 9:188-190, 167.
36. Houghten RA: General method for the rapid solid-phase synthesis of
large numbers of peptides: specificity of antigen-antibody interaction at
the level of individual amino acids. Proc Natl Acad Sci USA 1985,
82:5131-5135.
37. Escalante AA, Barrio E, Ayala FJ: Evolutionary origin of human and primate
malarias: evidence from the circumsporozoite protein gene. Mol Biol Evol
1995, 12:616-626.
38. Bendtsen JD, Nielsen H, von Heijne G, Brunak S: Improved prediction of
signal peptides: SignalP 3.0. J Mol Biol 2004, 340:783-795.
39. Krogh A, Larsson B, von Heijne G, Sonnhammer EL: Predicting
transmembrane protein topology with a hidden Markov model:
application to complete genomes. J Mol Biol 2001, 305:567-580.
40. TMHMM Server v. 2.0. [http://www.cbs.dtu.dk/services/TMHMM/].
41. Matuschewski K, Nunes AC, Nussenzweig V, Menard R: Plasmodium
sporozoite invasion into insect and mammalian cells is directed by the
same dual binding system. Embo J 2002, 21:1597-1606.
42. Green JL, Hinds L, Grainger M, Knuepfer E, Holder AA: Plasmodium
thrombospondin related apical merozoite protein (PTRAMP) is shed
from the surface of merozoites by PfSUB2 upon invasion of
erythrocytes. Mol Biochem Parasitol 2006, 150:114-117.
43. Wang L, Menting JG, Black CG, Stowers A, Kaslow DC, Hoffman SL,
Coppel RL: Differences in epitope recognition, isotype and titer of
antisera to Plasmodium falciparum merozoite surface protein 4 raised
by different modes of DNA or protein immunization. Vaccine 2000,
19:816-824.
44. Xainli J, Cole-Tobian JL, Baisor M, Kastens W, Bockarie M, Yazdani SS,
Chitnis CE, Adams JH, King CL: Epitope-specific humoral immunity to
Plasmodium vivax Duffy binding protein. Infect Immun 2003, 71:2508-2515.
doi:10.1186/1475-2875-9-283
Cite this article as: Mongui et al.: Identification and characterization of
the Plasmodium vivax thrombospondin-related apical merozoite protein.
Malaria Journal 2010 9:283.
Mongui et al. Malaria Journal 2010, 9:283
http://www.malariajournal.com/content/9/1/283
Page 10 of 10